GRAIL, Inc. (GRAL)
79.30
-3.24
(-3.92%)
USD |
NASDAQ |
Aug 26, 14:56
GRAIL Enterprise Value : 2.916B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 2.916B |
| August 24, 2026 | 2.650B |
| August 21, 2026 | 2.782B |
| August 20, 2026 | 2.712B |
| August 19, 2026 | 2.533B |
| August 18, 2026 | 2.396B |
| August 17, 2026 | 2.354B |
| August 14, 2026 | 2.261B |
| August 13, 2026 | 2.278B |
| August 12, 2026 | 2.309B |
| August 11, 2026 | 2.601B |
| August 10, 2026 | 2.573B |
| August 07, 2026 | 2.333B |
| August 06, 2026 | 2.062B |
| August 05, 2026 | 2.543B |
| August 04, 2026 | 2.477B |
| August 03, 2026 | 2.368B |
| July 31, 2026 | 2.292B |
| July 30, 2026 | 2.407B |
| July 29, 2026 | 2.063B |
| July 28, 2026 | 2.107B |
| July 27, 2026 | 2.212B |
| July 24, 2026 | 2.260B |
| July 23, 2026 | 2.372B |
| July 22, 2026 | 2.386B |
| Date | Value |
|---|---|
| July 21, 2026 | 2.477B |
| July 20, 2026 | 2.308B |
| July 17, 2026 | 2.473B |
| July 16, 2026 | 2.444B |
| July 15, 2026 | 2.551B |
| July 14, 2026 | 2.496B |
| July 13, 2026 | 2.437B |
| July 10, 2026 | 2.446B |
| July 09, 2026 | 2.615B |
| July 08, 2026 | 2.363B |
| July 07, 2026 | 2.302B |
| July 06, 2026 | 2.309B |
| July 02, 2026 | 2.317B |
| July 01, 2026 | 2.272B |
| June 30, 2026 | 2.279B |
| June 29, 2026 | 2.041B |
| June 26, 2026 | 1.939B |
| June 25, 2026 | 1.966B |
| June 24, 2026 | 1.884B |
| June 23, 2026 | 1.742B |
| June 22, 2026 | 1.782B |
| June 18, 2026 | 1.850B |
| June 17, 2026 | 1.673B |
| June 16, 2026 | 1.626B |
| June 15, 2026 | 1.688B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 12.32B |
| Oncolytics Biotech, Inc. | 103.70M |
| Sangamo Therapeutics, Inc. | 53.43M |
| Sarepta Therapeutics, Inc. | 2.256B |
| Anixa Biosciences, Inc. | 109.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -110.25M |
| Revenue (Quarterly) | 44.69M |
| Total Expenses (Quarterly) | 154.93M |
| EPS Diluted (Quarterly) | -2.557 |
| Gross Profit Margin (Quarterly) | -30.61% |
| Profit Margin (Quarterly) | -246.7% |
| Earnings Yield | -12.29% |
| Normalized Earnings Yield | -11.77 |